See the evolution of the NovaSure® and MyoSure® systems at AAGL View in browser
Visit Hologic’s booth #607 at AAGL
At AAGL, Hologic will be sharing its innovative surgical solutions designed to improve the lives of your patients with debilitating gynecologic conditions. Stop by booth #607 for:
Live demonstrations of the MyoSure® REACH device
A preview of the next NovaSure® device
Pending PMA approval. Not yet available for sale in the United States.
Exclusive one-on-one interviews with category key opinion leaders
Information about the tools and resources Hologic provides to support your practice
Visit Hologic at booth #607 to learn more!
The MyoSure hysteroscopic tissue removal system is intended for hysteroscopic intrauterine procedures by trained gynecologists to resect and remove tissue including submucous myomas, endometrial polyps and retained products of conception. It is not appropriate for patients who are or may be pregnant, or are exhibiting pelvic infection, cervical malignancies or previously diagnosed endometrial cancer.
NovaSure endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the NovaSure procedure can be dangerous. The NovaSure procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. NovaSure endometrial ablation is not a sterilization procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. Inform patients to contact you if they experience a possible side effect related to use of this product. For detailed benefit and risk information, please consult the IFU.